Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/35908Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 林文澧 | |
| dc.contributor.author | Cheng-Ni Liu | en |
| dc.contributor.author | 劉正暱 | zh_TW |
| dc.date.accessioned | 2021-06-13T07:48:05Z | - |
| dc.date.available | 2007-07-03 | |
| dc.date.copyright | 2006-07-03 | |
| dc.date.issued | 2005 | |
| dc.date.submitted | 2005-07-26 | |
| dc.identifier.citation | 參考文獻
Craig EA, Weissman JS, Horwich AL. 1994. Heat shock proteinsand molec- ular chaperones: mediators of protein conformation and turnover in the cell. Cell 78:365-372. Ellis RJ, van der Vies SM. 1991. Molecular chaperones. Annu Rev Biochem 60:321-347. Evgrafov OV, Mersiyanova I, Irobi J, Van Den Bosch L, Dierick I, Leung C L, Schagina O, Verpoorten N, Van Impe K, Fedotov V, Dadali E, Auer- Grumbach M, Windpassinger C, Wagner K, Mitrovic Z, Hilton-Jones D, Talbot K, Martin JJ, Vasserman N, Tverskaya S, Polyakov A, Liem RK, Gettemans J, Robberecht W, De Jonghe P, Timmerman V. 2004. Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet 36:602-6 Fernandez-Hojas R, Huie ML, Navarro C, Dominguez C, Roig M, Lopez- Coronas D, Teijeira S, Anyane-Yeboa K, Hirschhorn R. 2002. Identific- ation of six novel mutations in the acid alpha-glucosidase gene in three Spanish patients with infantile onset glycogen storage disease type II (Pompe disease). Neuromuscul Disord 12:159–166. Hendrick JP, Hartl F-U. 1993. Molecular chaperone functions ofheat-shock proteins. Annu Rev Biochem 62:349-384. Hendrick JP, Hartl F-U. 1995. The role of molecular chaperones in protein folding. FASEB J 9:1559-1569. Hermans MM, Kroos MA, van Beeumen J, Oostra BA, Reuser AJ. 1991. Human lysosomal alpha-glucosidase. Characterization of the catalytic site. J Biol Chem 266:13507–13512. Hermans MM, de Graaff E, Kroos MA, Wisselaar HA, WillemsenR, Oostra BA, Reuser AJ. 1993. The conservative substitution Asp-645-Glu in lys- osomal alpha-glucosidase affects transport and phosphorylation of the e- nzyme in an adult patient with glycogen-storage disease type II. Bioche- m J 289:687–693. Hermans MM, De Graaff E, Kroos MA, Mohkamsing S, Eussen BJ, Joosse M, Willemsen R, Kleijer WJ, Oostra BA, Reuser AJJ. 1994. The effect of a single base pair deletion (delta T525) and a C1634T missense muta- tion (pro545leu) on the expression of lysosomal alpha-glucosidase in pa- tients with glycogen storage disease type II. Hum Mol Genet 3: 2213– 2218. Hermans MMP, van Leenen D, Kroos MA, Reuser AJJ. 1997. Mutation de- tection in glycogen storage-disease type II by RT-PCR and automated sequencing. Biochem Biophys Res Commun 241:414–418. Hermans MMP, Kroos MA, Smeitink JAM, van der Ploeg AT, Kleijer WJ, Reuser AJJ. 1998. Glycogen storage disease type II: genetic and bioche- mical analysis of novel mutations in infantile patients from Turkish anc- estry. Hum Mutat 11:209–215. Hers HG. 1963. alpha-Glucosidase deficiency in generalized glycogen stora- ge disease (Pompe’s disease). Biochem J 86:11–16. Hirschhorn R, Huie ML. 1999. Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally ‘‘common’’ in white populations [letter; co- mment]. J Med Genet 36:85–86. Hirschhorn R, Reuser AJJ. 2001. Glycogen storage disease type II (GSDII). In: Scriver CR, Beaudet AL, Sly W, Valle D, editors. The metabolic and molecular bases of inherited disease. Chapter 135. New York: McGraw- Hill, Inc. Hoefsloot LH, Hoogeveen-Westerveld M, Kroos MA, van Beeumen J, Re- user AJ, Oostra BA. 1988. Primary structure and processing of lysoso- mal alpha-glucosidase; homology with the intestinal sucrase-isomaltase complex. EMBO Journal 7:1697–1704. Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJJ, Oostra BA.1990. Characterization of the human lysosomal alpha-glucosidase gene. Biochem J 272:493–497. Hermans Monique MP, Leenen Dik van, Kroos MA, Beesley CE, Van derP- loeg AT. 2004. Twenty-Two Novel Mutations in the Lysosomal αGlu- cosidase Gene(GAA) Underscore the Genotype-Phenotype Correlation in Glycogen Storage Disease Type II. Human Mutation 23:47-56. Huie ML, Chen AS, Brooks SS, Grix A, Hirschhorn R. 1994a. A de novo 13 -nt deletion, a newly identified C647W missense mutation and a delete- on of exon 18 in infantile onset glycogen storage disease type II (GSD II). Hum Mol Genet 3:1081–1087. Huie ML, Chen AS, Tsujino S, Shanske S, DiMauro S, Engel AG, Hirschho- rn R. 1994b. Aberrant splicing in adult onset glycogen storage disease t- ype II (GSDII): molecular identification of an IVS1 (_13T-G) mutation in a majority of patients and a novel IVS10 (+1GT-CT) mutation. Hum Mol Genet 3:2231–2236. Huie ML, Hirschhorn R, Chen AS, Martiniuk F, Zhong N. 1994c. Mutation at the catalytic site (M519V) in glycogen storage disease type II (Pom- pe disease). Hum Mutat 4:291–293. Huie ML, Menaker M, McAlpine PJ, Hirschhorn R. 1996. Identification of an E689K substitution as the molecular basis of the human acid a-gluc- osidase type 4 allozyme (GAA*4). Ann Hum Genet 60:365–368. Hwu WL, Leu MY, Hwa KY, Fan SW, Lee YM (2004) Molecular chaperon- nes affect GTP cyclohydrolase I mutations in dopa-responsive dystonia. Annals Neurol (in press) Ko TM, Hwu WL, Lin YW, Tseng LH, Hwa HL, Wang TR, Chuang SM. 1999. Molecular genetic study of Pompe disease in Chinese patients in Taiwan. Hum Mutat 13:380–384. Kroos MA, Van der Kraan M, Van Diggelen OP, Kleijer WJ, Reuser AJJ, Van den Boogaard MJ, Ausems MGEM, Ploos van Amstel HK, Poenaru L, Nicolino M, Wevers R. 1995. Glycogen storage disease type II: freq- uency of three common mutant alleles and their associated clinical phe- notypes studied in 121 patients. J Med Genet 32:836–837. Kroos MA, van Leenen D, Verbiest J, Reuser AJ, Hermans MM. 1998. Gly- cogen storage disease type II: identification of a dinucleotide deletion a- nd a common missense mutation in the lysosomal alpha-glucosidase ge- ne. Clin Genet 53:379–382. Lovering AL, Lee SS, Kim YW, Withers SG, Strynadka Natalie CJ. 2005. Mechanistic and Structural Analysis of a Family 31 α-Glycosidase and Its Glycosyl-enzyme Intermediate. J Biol Chem 280:2105-2115. Martiniuk F, Mehler M, Pellicer A, Tzall S, La Badie G, Hobart C, Ellenbo- gen A, Hirschhorn R. 1986. Isolation of a cDNA for human acid alpha- glucosidase and detection of genetic heterogeneity for mRNA in three alpha-glucosidase-deficient patients. Proc Natl Acad Sci USA 83:9641– 9644. Martiniuk F, Bodkin M, Tzall S, Hirschhorn R. 1990a. Identification of the base-pair substitution responsible for a human acid α-glucosidase alle- le with lower 'affinity' for glycogen (GAA 2) and transient gene expre- ssion in deficient cells. Am J Hum Genet 47:440–445. Martiniuk F, Mehler M, Tzall S, Meredith G, Hirschhorn R. 1990b.Sequence of the cDNA and 50-flanking region for human acid alpha-glucosidase detection of an intron in the 50 untranslated leader sequence, definition of 18-bp polymorphisms, and differences with previous cDNA and ami- no acid sequences. DNA Cell Biol 9:85–94. Martiniuk F, Mehler M, Bodkin M, Tzall S, Hirschhorn K, Zhong N, Hirsc hhorn R. 1991. Identification of a missense mutation in an adult-onset patient with glycogenosis type II expressing only one allele. DNA Cell Biol 10:681–687. Nicolino M, Puech JP, Letourneur F, Fardeau M, Kahn A, Poenaru L. 1997. Glycogen-storage disease type II (acid maltase deficiency):identification of a novel small deletion (delCC482+483) in French patients. Biochem Biophys Res Commun 235:138–141. Raben N, Lee E, Lee L, Hirschhorn R, Plotz PH. 1999. Novel mutations in African American patients with glycogen storage disease Type II. Muta- tions in brief no. 209. Online. Hum Mutat 13:83–84. Raben N, Plotz P, Byrne BJ. 2002. Acid alpha-glucosidase deficiency (glyc- ogenosis type II, Pompe disease). Curr Mol Med 2:145–166. Reuser AJ, Kroos M, Oude Elferink RP, Tager JM. 1985. Defects in synthe- sis, phosphorylation, and maturation of acid alpha glucosidase in glycol- genosis type II. J Biol Chem 260:8336–8341. Reuser AJ, Kroos M, Willemsen R, Swallow D, Tager JM, Galjaard H.1987. Clinical diversity in glycogenosis type II. Biosynthesis and in situ local- ization of acid alpha-glucosidase in mutant fibroblasts. J Clin Invest 79: 1689–1699. Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse C, Paul C, Wieske M, Arrigo AP, Buchner J, Gaestel M. 1999. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem 274:18947-56. Schlesinger MJ. 1990. Heat shock proteins. J Biol Chem 265:12111-12114. Shieh JJ, Wang LY, Lin CY. 1994. Point mutation in Pompe disease in Ch- inese. J Inherit Metab Dis 17:145–148. Shieh JJ, Lin CY. 1996. Identification of a small deletion in one allele of pa- tients with infantile form of glycogen storage disease type II. Biochem Biophys Res Commun 219:322–326. Shieh JJ, Lin CY. 1998. Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect. Hum Mutat 11: 306–312. Tsujino S, Huie M, Kanazawa N, Sugie H, Goto Y, Kawai M, Nonaka I, Hi- rschhorn R, Sakaragawa N. 2000. Frequent mutations in Japanese patie- nts with acid maltase deficiency. Neuromuscul Disord 10:599–603. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme- Dijkhuis A, Van der Ploeg AT. 2000. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356:397–398. Van der Kraan M, Kroos MA, Joosse M, Bijvoet AG, Verbeet MP, Kleijer WJ, Reuser AJ. 1994. Deletion of exon 18 is a frequent mutation in gly- cogen storage disease type II. Biochem Biophys Res Commun 203:153–1541. Wisselaar HA, Kroos MA, Hermans MM, van Beeumen J, Reuser AJ. 1993. Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem 268:2223- 2231. Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo AP, Rubi- nsztein DC. 2002. Heat shock protein 27 prevents cellular polyglutamin- e toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet 11:1137-51. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/35908 | - |
| dc.description.abstract | 龐貝氏症(Pompe’s disease)是一種肝醣儲積症(Glycogen storage disease, GSD),又稱為肝醣儲積症第二型(GSD II)。是由於先天缺乏溶小體酵素-酸性麥芽糖酶(Acid Maltase,又稱acid α-glucosidase, GAA),使得進入溶小體的肝醣無法被分解而持續堆積,進而影響到細胞的功能。臨床上依發病年齡分為嬰兒型、青少年型及成人型。龐貝氏症確定診斷的方法為測定皮膚纖維芽細胞或血液中GAA酵素活性。通常患者的酵素活性很低(<5%),而帶原者的活性會介於正常人和患者之間。臨床上發現,部分帶原者的酵素活性偏低,約只有正常人5 ~ 10%,可能會增加檢測困難度。因此,我們認為可能存在某些因數會影響酸性麥芽糖酶的表現,如基因多型性或其他機轉,影響到酸性麥芽糖酶的蛋白質穩定性。在本實驗室近年來的研究,發現熱休克蛋白Hsp27對於突變蛋白GTP cyclohydrolase I的dominant-negative effect會有影響。Hsp27是一種small heat shock蛋白,和蛋白質摺疊、細胞骨架之穩定性,以及細胞凋亡有關。突變酸性麥芽糖酶可能在某些情況下,如Hsp27存在下,其蛋白質穩定性會有所改變,也可能會受到其他因數的影響,導致細胞酵素活性降到如此的低。
本研究進行的方法(1)分析所有個案的GAA酵素活性、mRNA與蛋白質表現量。(2)藉著基因序列分析找尋是否有基因多型性的存在,與突變蛋白GAA酵素活性具有關聯性。(3)以表現Hsp27的質體轉染龐貝氏症患者或是帶原者的皮膚纖維芽細胞,瞭解Hsp27對於突變蛋白GAA酵素活性是否具有調控的能力。 本實驗結果證實GAA酵素活性表現與蛋白質表現量有正相關性。也證實GAA突變蛋白的存在。RNA實驗結果顯示,帶原者的GAA蛋白表現量和其mRNA間並無絕對相關性存在。以蛋白結構推測,GAA突變蛋白與正常蛋白具有差異性。雖然基因多型性可能會影響GAA突變蛋白的穩定性,在基因序列分析中,也發現許多序列多型性,並形成三個區塊,但並無特殊的基因多型性與酵素活性間有關聯性。Hsp27 -S3D實驗中發現Hsp27-S3D會降低患者與帶原者的酵素活性。 影響GAA酵素活性的因數,還是有其他基因多型性,或其他分子伴隨者調控的可能。本研究主要目的希望能應用於未來的臨床診斷及治療,在臨床上提供更精確診斷,治療上能有其他新藥物。我們的研究指出蛋白質的穩定性是影響酵素活性的重要因數。可能在基因的其他位置,例如是intron仍存在著有影響的序列多型性。或是細胞內的其他熱休克蛋白會影響GAA蛋白的穩定性,這些都還待進一步之研究。 | zh_TW |
| dc.description.abstract | Pompe’s disease is a lysosomal storage disease involving the storage of glycogen. It is used to be called type II glycogenosis. The etiology of this disease is the deficiency of acid maltase (or acid alpha-glucosidase, GAA). The deficiency of GAA leads to a progressive storage of glycogen in the lysosome, which affects the function of the cells. According to the onset clinically, there are three subtypes – infantile, juvenile, and adult type. The diagnosis of Pompe’s disease depends on the measurement of GAA activity in either skin fibroblast or in peripheral blood mononuclear cells. Theoretically, GAA activities in obligatory carriers should be 50% of normal. However, we frequently met carriers with GAA activities as low as 5~10% of normal. The current hypothesis is the presence of some important factors, ex. polymorphism or some other mechanisms that will alter the stability of GAA.
In our previous studies, Hsp27 can alter the stability of the GTP-cyclohydrolase I protein. Hsp27 is a member of the small HSP that is involved in protein folding, stability of the cytoskeleton, and cell apoptosis. It is possible that the stability of GAA will be changed under certain circumferences, and then causes the excessive low GAA activity in some individuals. In this study, we are going to perform the assays: (1) the GAA activity, mRNA, and protein expression; (2) the gene polymorphism analysis; (3) to overexpress Hsp27 in skin fibroblasts from either Pompe’s patients or the carriers. We will observe the changes of GAA protein by the western blot analysis, and also GAA activities by enzyme assays, to see if these parameters will be changed by the expression of Hsp27. Special interests will be on Pompe’s carriers with excessive low GAA activities. In the study, there is a positive correlation between the GAA activity and the protein expression. From the RNA study, there is no correlation between the expression of the GAA protein and of the mRNA. From the structure analysis, the polymorphism (V816I) may influence the stability of mutant GAA protein. We also find some polymorphisms and form three blocks in the gene polymorphism study. But, no relation between the polymorphisms and the GAA activity. The data of the Hsp27 study shows Hsp-S3D will decrease the GAA activity, either in the patients or carriers. There still exists the possibility of some other factors that will influence the GAA activity, ex. Polymorphisms, or heat shock proteins. This study will contribute significantly the knowledge of the pathogenesis of disease, the mechanism of changes in protein stability, the diagnostic technology, and also deeply to the future treatment of the diseases, including those with similar molecular mechanisms. Our data showed the stability of GAA protein is one important factor to the GAA activity. Maybe some polymorphisms exists in some position of the GAA gene, ex. Intron, that will play some roles. Or, the other Hsp in the cells may affect the stability of the GAA protein. Those all will be needed further study. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-13T07:48:05Z (GMT). No. of bitstreams: 1 ntu-94-R92548021-1.pdf: 2340063 bytes, checksum: d93bb195df5657c8582d778e4df742de (MD5) Previous issue date: 2005 | en |
| dc.description.tableofcontents | 目 錄
標題 …….……………………………………………………... 頁數 中文摘要 ……………………………………………………… 1 英文摘要 ……………………………………………………… 2 研究背景 ……………………………………………………… 3 龐貝氏症 ………………………………………………… 3 酸性麥芽糖酶 …………………………………………… 4 熱休克蛋白 ……………………………………………… 7 研究動機 ……………………………………………………… 11 龐貝氏症帶原者具有極低GAA的酵素活性 …………. 11 假說 ……………………………………………………… 12 實驗設計 ………………………………………………… 12 材料與方法 …………………………………………………… 14 病患檢體採集 ………………….………………………... 14 質體 ………………….…………………………………... 14 細胞培養與轉染實驗 ………………….………………... 14 細胞萃取物的製備 ……………………………………… 15 蛋白質定量 ………………….………………….……….. 15 西方墨點法 ………………….…………………………... 16 酸性麥芽糖酵素活性檢驗 ……………………………… 17 萃取RNA ………………………………………………... 17 Rverse transcription ……………………………………… 18 PCR ………………………………………………………. 19 結果 …………………………………………………………... 20 龐貝氏症帶原者的GAA酵素活性差異大 ……………. 20 GAA蛋白質的表現與酵素活性關性 ………………….. 20 GAA基因的序列分析 ………………………………….. 22 分子伴隨者對於GAA的影響 …………………………. 23 GAA mRNA與GAA蛋白質表現之量關性 …………... 24 討論 ………………….………………….…………………….. 26 龐貝氏症帶原者之酵素性 ……………………………… 26 酵素活性的決定素 ………………….…………………... 27 蛋白質表現之決定素 ………………….………………... 28 GAA突變與酵素活性及穩定性 ………………….……. 29 部分龐貝氏症帶原者酵素活性偏低之原因 …………… 32 結論…………………………………………………………….. 33 圖表 …………………………………………………………… 34 圖一a. 龐貝氏症帶原者的GAA酵素活性分佈圖 …… 34 圖一b. 龐貝氏症帶原者的GAA酵素活性分佈圖 …… 34 圖二a. GAA酵素活性與蛋白質的表現 ……………….. 35 圖二b. GAA酵素活性與蛋白質的表現 ……………….. 35 圖二c. GAA酵素活性與蛋白質的表現 ……………….. 35 圖二d. GAA酵素活性與蛋白質的表現 ……………….. 36 圖二e. GAA酵素活性與蛋白質的表現 ……………….. 36 圖三 GAA酵素活性與蛋白質表現量關係圖 …………. 37 表一 龐貝氏症帶原者與病人的GAA 突變位置與SNP . 38 圖四 GAA基因的序列分析之蛋白質二級結構變異 …. 39 圖五a. 分子伴隨者對於正常人GAA的影響 ………… 40 圖五b. 分子伴隨者對於正常人GAA的影響 ………… 40 圖五c. 分子伴隨者對於帶原者GAA的影響 ………… 41 圖五d. 分子伴隨者對於帶原者GAA的影響 ………… 41 圖五e. 分子伴隨者對於病人GAA的影響 …………… 42 圖五f. 分子伴隨者對於病人GAA的影響 ……………. 42 圖六a. 分子伴隨者對於GAA的影響比較圖 …………. 43 圖六b. 分子伴隨者對於GAA的影響比較圖 …………. 43 圖七. GAA蛋白質表現量與RNA表現量 ……………… 44 參考文獻 ……………………………………………………….. 45 | |
| dc.language.iso | zh-TW | |
| dc.subject | 龐貝氏症 | zh_TW |
| dc.subject | Pompe’s disease | en |
| dc.title | 龐貝氏症患者及帶原者酵素活性差異性之原因 | zh_TW |
| dc.title | Etiology of enzyme activity variability in Pompe’s disease | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 93-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 胡務亮 | |
| dc.contributor.oralexamcommittee | 鄔哲源,謝松蒼 | |
| dc.subject.keyword | 龐貝氏症, | zh_TW |
| dc.subject.keyword | Pompe’s disease, | en |
| dc.relation.page | 50 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2005-07-26 | |
| dc.contributor.author-college | 工學院 | zh_TW |
| dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
| Appears in Collections: | 醫學工程學研究所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| ntu-94-1.pdf Restricted Access | 2.29 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
